#1 Clinical Trials Search in Europe

Protein S

Recent clinical trials are investigating the use of Protein S, a crucial component in blood coagulation, as part of combination therapies for managing various bleeding disorders and anticoagulation reversal. These studies aim to evaluate the safety and efficacy of treatments containing Protein S along with other coagulation factors in different clinical scenarios, from urgent surgery to major bleeding events.

Table of Contents

What is Protein S?

Protein S is a naturally occurring protein in the human body that plays a crucial role in the blood clotting process. It is one of several important components found in blood plasma that help regulate coagulation, which is the process of blood clot formation[1]. Protein S is also known by other names, including vitamin K-dependent protein S and blood-coagulation factor XIV[2].

Function of Protein S

The primary function of Protein S is to act as a natural anticoagulant, which means it helps prevent excessive blood clotting. It works in conjunction with another protein called Protein C to regulate the coagulation cascade, which is a series of chemical reactions that lead to the formation of blood clots[1].

Specifically, Protein S acts as a cofactor for activated Protein C. Together, they inactivate certain clotting factors (Factor Va and Factor VIIIa), which helps to slow down the clotting process and prevent the formation of unnecessary or harmful blood clots[2].

Medical Uses

Protein S, along with other coagulation factors, is used in medical treatments primarily for managing bleeding disorders and reversing the effects of certain anticoagulant medications. Some of the medical uses include:

  • Reversing anticoagulation: Protein S is a component of prothrombin complex concentrates (PCCs) used to reverse the effects of anticoagulant drugs, particularly in emergency situations[1].
  • Managing bleeding in patients with factor deficiencies: PCCs containing Protein S can be used to treat or prevent bleeding in patients with deficiencies of certain coagulation factors[1].
  • Emergency surgery: In patients requiring urgent surgery who are on anticoagulant therapy, products containing Protein S may be used to quickly reverse the anticoagulant effects and reduce the risk of excessive bleeding during the procedure[1].

Clinical Trials and Research

Several clinical trials are investigating the use of products containing Protein S for various medical conditions:

  • Reversal of anticoagulation in emergency situations: A Phase 3 trial is studying the effectiveness of a prothrombin complex concentrate (which includes Protein S) in reversing the effects of factor Xa inhibitors (a type of anticoagulant) in patients requiring urgent surgery or experiencing major bleeding[1].
  • Thrombosis prevention in orthopedic surgery: Another study is investigating different thrombosis prevention strategies, including the use of products containing coagulation factors, in patients undergoing total hip or knee replacement surgery[2].
  • Management of major bleeding: A clinical trial is assessing the effectiveness of a four-factor prothrombin complex concentrate (which includes Protein S) in managing acute major bleeding in patients taking direct oral anticoagulants[3].

Safety and Side Effects

While products containing Protein S are generally considered safe when used as directed, there are potential risks and side effects to be aware of:

  • Thrombotic events: In rare cases, the use of prothrombin complex concentrates may increase the risk of blood clot formation[1].
  • Allergic reactions: Some patients may experience allergic reactions to the components of these products[3].
  • Transmission of infectious agents: As these products are derived from human plasma, there is a theoretical risk of transmitting infectious agents, although modern manufacturing processes have greatly reduced this risk[1].

It’s important to note that these products should only be used under the supervision of a healthcare professional, who will weigh the potential benefits against the risks for each individual patient.

Conclusion

Protein S plays a vital role in the body’s natural blood clotting processes. Its inclusion in medical products, particularly prothrombin complex concentrates, has made it an important tool in managing various bleeding disorders and reversing the effects of anticoagulant medications. Ongoing research continues to explore new applications and refine existing treatments involving Protein S, with the goal of improving patient outcomes in emergency situations and various medical procedures.

Trial Focus Key Objectives Patient Population Treatment
Anticoagulation reversal for urgent surgery Evaluate efficacy and safety of TAK-330 vs. standard care Patients on Factor Xa inhibitors needing urgent surgery TAK-330 (contains Protein S and other factors)
VTE prevention after joint replacement Compare individualized vs. standard thrombosis prophylaxis Patients undergoing hip or knee replacement Various, including Protein S-containing products
Meningococcal B vaccination in asplenic adults Assess immunogenicity and safety of vaccine strategies Adults with asplenia Meningococcal B vaccines (not directly related to Protein S)
Major bleeding management in DOAC patients Evaluate haemostatic effectiveness of OCTAPLEX Patients with major bleeding on Factor Xa inhibitors OCTAPLEX (contains Protein S and other factors)

FAQ

  • What is Protein S and why is it important in blood clotting? Protein S is a natural anticoagulant protein that helps regulate blood clotting. It works with other proteins to prevent excessive clot formation. In these trials, Protein S is being studied as part of combination therapies to manage bleeding and reverse anticoagulation effects.
  • What conditions are being studied in these clinical trials involving Protein S? The trials are investigating the use of Protein S-containing therapies in various situations, including reversing anticoagulation in patients needing urgent surgery, managing major bleeding in patients on blood thinners, and preventing blood clots after hip or knee replacement surgery.
  • How is Protein S administered in these trials? Protein S is not given alone, but as part of combination products that contain multiple coagulation factors. These are typically administered intravenously as infusions or injections.
  • What are the potential benefits of using Protein S-containing therapies? The potential benefits include more effective reversal of anticoagulation, better control of bleeding events, and improved blood clot prevention in high-risk situations. Researchers hope these therapies will provide more targeted and efficient coagulation management.
  • Are there any risks associated with Protein S-containing treatments? As with any blood product or coagulation therapy, there are potential risks such as allergic reactions or excessive blood clotting. The clinical trials are designed to carefully monitor for any adverse effects and assess the overall safety of these treatments.

Ongoing Clinical Trials on Protein S

  • Study on Venous Thromboembolism Prevention with Enoxaparin Sodium and Drug Combination for Patients Undergoing Total Hip or Knee Replacement

    Recruiting

    3 1 1 1
    Investigated drugs:
    The Netherlands

  • Study on TAK-330 for Reversing Anticoagulation in Patients on Factor Xa Inhibitors Needing Urgent Surgery

    Recruiting

    3 1 1 1
    Investigated diseases:
    Investigated drugs:
    Austria Belgium Czechia France Germany Greece +5

  • Study on the Effects of Apixaban Absorption in Patients Undergoing Roux-en-Y Gastric Bypass Surgery

    Not yet recruiting

    3 1 1 1
    Investigated drugs:
    The Netherlands

  • Study on the Effectiveness of Human Coagulation Factor IX and Drug Combination for Patients with Major Bleeding on Factor Xa Inhibitor Therapy

    Not recruiting

    3 1 1 1
    Investigated drugs:
    Austria Croatia Germany Italy Poland Spain

Glossary

  • Anticoagulation: The process of hindering blood clot formation, often achieved through medication (blood thinners).
  • Coagulation factors: Proteins in the blood that work together to form blood clots.
  • Direct Oral Anticoagulants (DOACs): A type of blood thinner taken by mouth that directly inhibits specific coagulation factors.
  • Factor Xa inhibitors: A class of anticoagulant drugs that work by blocking the action of clotting factor Xa.
  • Haemostasis: The process which causes bleeding to stop, involving blood clotting and the repair of damaged blood vessels.
  • Prothrombin Complex Concentrate (PCC): A mixture of blood clotting factors used to reverse the effects of blood thinners or treat certain bleeding disorders.
  • Thromboembolism: The formation of a blood clot in a blood vessel that breaks loose and is carried by the blood stream to obstruct another vessel.
  • Venous Thromboembolism (VTE): A condition where blood clots form in the veins, typically in the legs or lungs.
  • Asplenia: The absence of a normal functioning spleen, either due to surgical removal or disease.
  • Meningococcal disease: A serious bacterial infection caused by Neisseria meningitidis that can lead to meningitis or sepsis.

References

  1. http://clinicaltrials.eu/trial/study-on-tak-330-for-reversing-anticoagulation-in-patients-on-factor-xa-inhibitors-needing-urgent-surgery/
  2. http://clinicaltrials.eu/trial/study-on-venous-thromboembolism-prevention-with-enoxaparin-sodium-and-drug-combination-for-patients-undergoing-total-hip-or-knee-replacement/
  3. http://clinicaltrials.eu/trial/study-on-the-effectiveness-of-human-coagulation-factor-ix-and-drug-combination-for-patients-with-major-bleeding-on-factor-xa-inhibitor-therapy/